141 related articles for article (PubMed ID: 36545921)
21. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
Front Oncol; 2022; 12():980765. PubMed ID: 36033444
[TBL] [Abstract][Full Text] [Related]
22. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
23. Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France.
Sassolas B; Leccia MT; Godard C; Benmahamed L; Flinois A; Levy-Bachelot L; Bédane C
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):587-594. PubMed ID: 28960564
[TBL] [Abstract][Full Text] [Related]
24. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
25. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and
Asad Zadeh Vosta Kolaei F; Cai B; Kanakamedala H; Kim J; Doban V; Zhang S; Shi M
Front Oncol; 2022; 12():786124. PubMed ID: 35280795
[TBL] [Abstract][Full Text] [Related]
26. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
[TBL] [Abstract][Full Text] [Related]
27. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
28. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
Badiola LB; Milagro NL; Lavín DC; Peraita SL; Ibarbia MA; Kareaga MM; Fernández Del Rivero TP; Otero DSP; López VA; Fernández CÁ; Emborujo AL; Arnaiz IG; Rodríguez RF; Sagastibeltza N; Duran I;
Semin Oncol; 2024 Mar; ():. PubMed ID: 38604897
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract][Full Text] [Related]
30. Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.
Hill MV; Vidri RJ; Deng M; Handorf E; Olszanski AJ; Farma JM
Melanoma Res; 2022 Apr; 32(2):79-87. PubMed ID: 35254330
[TBL] [Abstract][Full Text] [Related]
31. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract][Full Text] [Related]
32. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract][Full Text] [Related]
33. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract][Full Text] [Related]
34. A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern.
Kerrigan K; Jo Y; Chipman J; Haaland B; Puri S; Akerley W; Patel S
JTO Clin Res Rep; 2022 Mar; 3(3):100280. PubMed ID: 35243411
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
36. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
[TBL] [Abstract][Full Text] [Related]
37. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
39. Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.
Marconcini R; Fava P; Nuzzo A; Manacorda S; Ferrari M; De Rosa F; De Tursi M; Tanda ET; Consoli F; Minisini A; Pimpinelli N; Morgese F; Bersanelli M; Tucci M; Saponara M; Parisi A; Ocelli M; Bazzurri S; Massaro G; Morganti R; Ciardetti I; Stanganelli I
Front Oncol; 2022; 12():917999. PubMed ID: 36046043
[TBL] [Abstract][Full Text] [Related]
40. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
